Prediction of radiation doses from therapy using tracer studies with iodine-131-labeled antibodies

Diane A. DeNardo, Gerald L. DeNardo, Aina Yuan, Sui Shen, Sally J. DeNardo, Daniel J. Macey, Kathleen R. Lamborn, Marc Mahe, Mark W. Groch, William D. Erwin

    Research output: Contribution to journalArticle

    36 Citations (Scopus)

    Abstract

    Tracer pharmacokinetic studies are often used in treatment planning for radionuclide therapy including radioimmunotherapy. This study evaluates the validity of using tracer studies to predict radiation doses from therapy with the same radiolabeled antibody. Methods: Quantitative imaging and blood radioactivity were used to obtain the pharmacokinetics and radiation doses that were delivered to the total body, blood, marrow, lungs, liver, kidneys, thyroid, spleen and tumors. Tracer and therapy data for eight patients with lymphoma and one patient with breast cancer were compared using linear regression statistics. Doses of 131I-labeled antibody for the tracer studies ranged from 0.1 to 0.4 GBq (2 to 10 mCi), and therapy doses ranged from 0.7 to 5.6 GBq (20 to 150 mCi). Results: Radiation doses to tissues and, in particular, the bone marrow and tumors were reliably predicted from tracer studies. In this group of patients, median dose to marrow from marrow targeting, total body and blood was 9.2 cGy/GBq for tracer studies and 7.6 cGy/GBq for therapy studies with a median difference of 0.5 cGy/GBq. Median dose to tumors was 81.1 cGy/GBq for tracer studies and 70.3 cGy/GBq for therapy studies with a median difference of 5.9 cGy/GBq. Conclusion: In these patients, tracer studies were predictive of the radiation doses from therapy for total body, major organs and tumors. The radiation doses to marrow and tumors, which are the usual determinants of the therapeutic index, correlated well between tracer and therapy studies (r > 0.95).

    Original languageEnglish (US)
    Pages (from-to)1970-1975
    Number of pages6
    JournalJournal of Nuclear Medicine
    Volume37
    Issue number12
    StatePublished - Dec 1996

    Fingerprint

    Iodine
    Radiotherapy
    Antibodies
    Bone Marrow
    Therapeutics
    Radiation
    Neoplasms
    Pharmacokinetics
    Radioimmunotherapy
    Radioisotopes
    Radioactivity
    Linear Models
    Lymphoma
    Thyroid Gland
    Spleen
    Breast Neoplasms
    Kidney
    Lung
    Liver

    Keywords

    • antibody
    • iodine-131
    • radiation dosimetry
    • radioimmunotherapy
    • therapeutic nuclear medicine
    • treatment planning

    ASJC Scopus subject areas

    • Radiology Nuclear Medicine and imaging

    Cite this

    DeNardo, D. A., DeNardo, G. L., Yuan, A., Shen, S., DeNardo, S. J., Macey, D. J., ... Erwin, W. D. (1996). Prediction of radiation doses from therapy using tracer studies with iodine-131-labeled antibodies. Journal of Nuclear Medicine, 37(12), 1970-1975.

    Prediction of radiation doses from therapy using tracer studies with iodine-131-labeled antibodies. / DeNardo, Diane A.; DeNardo, Gerald L.; Yuan, Aina; Shen, Sui; DeNardo, Sally J.; Macey, Daniel J.; Lamborn, Kathleen R.; Mahe, Marc; Groch, Mark W.; Erwin, William D.

    In: Journal of Nuclear Medicine, Vol. 37, No. 12, 12.1996, p. 1970-1975.

    Research output: Contribution to journalArticle

    DeNardo, DA, DeNardo, GL, Yuan, A, Shen, S, DeNardo, SJ, Macey, DJ, Lamborn, KR, Mahe, M, Groch, MW & Erwin, WD 1996, 'Prediction of radiation doses from therapy using tracer studies with iodine-131-labeled antibodies', Journal of Nuclear Medicine, vol. 37, no. 12, pp. 1970-1975.
    DeNardo, Diane A. ; DeNardo, Gerald L. ; Yuan, Aina ; Shen, Sui ; DeNardo, Sally J. ; Macey, Daniel J. ; Lamborn, Kathleen R. ; Mahe, Marc ; Groch, Mark W. ; Erwin, William D. / Prediction of radiation doses from therapy using tracer studies with iodine-131-labeled antibodies. In: Journal of Nuclear Medicine. 1996 ; Vol. 37, No. 12. pp. 1970-1975.
    @article{80655a8895fe4219bf188d5e4632a57d,
    title = "Prediction of radiation doses from therapy using tracer studies with iodine-131-labeled antibodies",
    abstract = "Tracer pharmacokinetic studies are often used in treatment planning for radionuclide therapy including radioimmunotherapy. This study evaluates the validity of using tracer studies to predict radiation doses from therapy with the same radiolabeled antibody. Methods: Quantitative imaging and blood radioactivity were used to obtain the pharmacokinetics and radiation doses that were delivered to the total body, blood, marrow, lungs, liver, kidneys, thyroid, spleen and tumors. Tracer and therapy data for eight patients with lymphoma and one patient with breast cancer were compared using linear regression statistics. Doses of 131I-labeled antibody for the tracer studies ranged from 0.1 to 0.4 GBq (2 to 10 mCi), and therapy doses ranged from 0.7 to 5.6 GBq (20 to 150 mCi). Results: Radiation doses to tissues and, in particular, the bone marrow and tumors were reliably predicted from tracer studies. In this group of patients, median dose to marrow from marrow targeting, total body and blood was 9.2 cGy/GBq for tracer studies and 7.6 cGy/GBq for therapy studies with a median difference of 0.5 cGy/GBq. Median dose to tumors was 81.1 cGy/GBq for tracer studies and 70.3 cGy/GBq for therapy studies with a median difference of 5.9 cGy/GBq. Conclusion: In these patients, tracer studies were predictive of the radiation doses from therapy for total body, major organs and tumors. The radiation doses to marrow and tumors, which are the usual determinants of the therapeutic index, correlated well between tracer and therapy studies (r > 0.95).",
    keywords = "antibody, iodine-131, radiation dosimetry, radioimmunotherapy, therapeutic nuclear medicine, treatment planning",
    author = "DeNardo, {Diane A.} and DeNardo, {Gerald L.} and Aina Yuan and Sui Shen and DeNardo, {Sally J.} and Macey, {Daniel J.} and Lamborn, {Kathleen R.} and Marc Mahe and Groch, {Mark W.} and Erwin, {William D.}",
    year = "1996",
    month = "12",
    language = "English (US)",
    volume = "37",
    pages = "1970--1975",
    journal = "Journal of Nuclear Medicine",
    issn = "0161-5505",
    publisher = "Society of Nuclear Medicine Inc.",
    number = "12",

    }

    TY - JOUR

    T1 - Prediction of radiation doses from therapy using tracer studies with iodine-131-labeled antibodies

    AU - DeNardo, Diane A.

    AU - DeNardo, Gerald L.

    AU - Yuan, Aina

    AU - Shen, Sui

    AU - DeNardo, Sally J.

    AU - Macey, Daniel J.

    AU - Lamborn, Kathleen R.

    AU - Mahe, Marc

    AU - Groch, Mark W.

    AU - Erwin, William D.

    PY - 1996/12

    Y1 - 1996/12

    N2 - Tracer pharmacokinetic studies are often used in treatment planning for radionuclide therapy including radioimmunotherapy. This study evaluates the validity of using tracer studies to predict radiation doses from therapy with the same radiolabeled antibody. Methods: Quantitative imaging and blood radioactivity were used to obtain the pharmacokinetics and radiation doses that were delivered to the total body, blood, marrow, lungs, liver, kidneys, thyroid, spleen and tumors. Tracer and therapy data for eight patients with lymphoma and one patient with breast cancer were compared using linear regression statistics. Doses of 131I-labeled antibody for the tracer studies ranged from 0.1 to 0.4 GBq (2 to 10 mCi), and therapy doses ranged from 0.7 to 5.6 GBq (20 to 150 mCi). Results: Radiation doses to tissues and, in particular, the bone marrow and tumors were reliably predicted from tracer studies. In this group of patients, median dose to marrow from marrow targeting, total body and blood was 9.2 cGy/GBq for tracer studies and 7.6 cGy/GBq for therapy studies with a median difference of 0.5 cGy/GBq. Median dose to tumors was 81.1 cGy/GBq for tracer studies and 70.3 cGy/GBq for therapy studies with a median difference of 5.9 cGy/GBq. Conclusion: In these patients, tracer studies were predictive of the radiation doses from therapy for total body, major organs and tumors. The radiation doses to marrow and tumors, which are the usual determinants of the therapeutic index, correlated well between tracer and therapy studies (r > 0.95).

    AB - Tracer pharmacokinetic studies are often used in treatment planning for radionuclide therapy including radioimmunotherapy. This study evaluates the validity of using tracer studies to predict radiation doses from therapy with the same radiolabeled antibody. Methods: Quantitative imaging and blood radioactivity were used to obtain the pharmacokinetics and radiation doses that were delivered to the total body, blood, marrow, lungs, liver, kidneys, thyroid, spleen and tumors. Tracer and therapy data for eight patients with lymphoma and one patient with breast cancer were compared using linear regression statistics. Doses of 131I-labeled antibody for the tracer studies ranged from 0.1 to 0.4 GBq (2 to 10 mCi), and therapy doses ranged from 0.7 to 5.6 GBq (20 to 150 mCi). Results: Radiation doses to tissues and, in particular, the bone marrow and tumors were reliably predicted from tracer studies. In this group of patients, median dose to marrow from marrow targeting, total body and blood was 9.2 cGy/GBq for tracer studies and 7.6 cGy/GBq for therapy studies with a median difference of 0.5 cGy/GBq. Median dose to tumors was 81.1 cGy/GBq for tracer studies and 70.3 cGy/GBq for therapy studies with a median difference of 5.9 cGy/GBq. Conclusion: In these patients, tracer studies were predictive of the radiation doses from therapy for total body, major organs and tumors. The radiation doses to marrow and tumors, which are the usual determinants of the therapeutic index, correlated well between tracer and therapy studies (r > 0.95).

    KW - antibody

    KW - iodine-131

    KW - radiation dosimetry

    KW - radioimmunotherapy

    KW - therapeutic nuclear medicine

    KW - treatment planning

    UR - http://www.scopus.com/inward/record.url?scp=12644301188&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=12644301188&partnerID=8YFLogxK

    M3 - Article

    C2 - 8970516

    AN - SCOPUS:12644301188

    VL - 37

    SP - 1970

    EP - 1975

    JO - Journal of Nuclear Medicine

    JF - Journal of Nuclear Medicine

    SN - 0161-5505

    IS - 12

    ER -